Clinical and practical considerations in the pharmacologic management of narcolepsy  by Thorpy, Michael J. & Dauvilliers, Yves
Review Article
Clinical and practical considerations in the pharmacologic
management of narcolepsy
Michael J. Thorpy a,*, Yves Dauvilliers b
a Sleep-Wake Disorders Center, Monteﬁore Medical Center, Bronx, NY, USA
b National Reference Network for Narcolepsy, Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, INSERM
U1061, France
A R T I C L E I N F O
Article history:
Received 17 June 2014
Received in revised form 7 October 2014
Accepted 9 October 2014







A B S T R A C T
Despite published treatment recommendations and the availability of approved and off-label pharma-
cologic therapies for narcolepsy, the clinical management of this incurable, chronic neurologic disorder
remains challenging. While treatment is generally symptomatically driven, decisions regarding which
drug(s) to use need to take into account a variety of factors that may affect adherence, eﬃcacy, and tol-
erability. Type 1 narcolepsy (predominantly excessive daytime sleepiness with cataplexy) or type 2
narcolepsy (excessive daytime sleepiness without cataplexy) may drive treatment decisions, with con-
sideration given either to a single drug that targets multiple symptoms or to multiple drugs that each
treat a speciﬁc symptom. Other drug-related characteristics that affect drug choice are dosing regi-
mens, tolerability, and potential drug–drug interactions. Additionally, the patient should be an active
participant in treatment decisions, and the main symptomatic complaints, treatment goals, psychoso-
cial setting, and use of lifestyle substances (ie, alcohol, nicotine, caffeine, and cannabis) need to be discussed
with respect to treatment decisions. Although there is a lack of narcolepsy-speciﬁc instruments for moni-
toring therapeutic effects, clinically relevant subjective and objective measures of daytime sleepiness (eg,
Epworth Sleepiness Scale and Maintenance of Wakefulness Test) can be used to provide guidance on
whether treatment goals are being met. These considerations are discussed with the objective of pro-
viding clinically relevant recommendations for making treatment decisions that can enhance the effective
management of patients with narcolepsy.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Narcolepsy, an underdiagnosed, incurable, chronic neurologic dis-
order, produces dysregulation of the sleep–wake cycle with excessive
daytime sleepiness (EDS) and rapid eyemovement (REM) sleep phe-
nomena including cataplexy, hypnagogic hallucinations, and sleep
paralysis. The estimated prevalence of narcolepsy is 0.05% of the
general population [1,2].
Recent advances in the pathophysiology [3], which have re-
sulted in revisions to the diagnostic criteria [4,5], indicate that
narcolepsy has an immunologic basis, with autoimmune compo-
nents that contribute to the characteristic loss of orexin (hypocretin)-
producing neurons in genetically predisposed individuals [6,7].
Animal narcolepsy models and optogenetic device studies have
shown that hypocretin maintains wakefulness, increases arousal,
and suppresses REM and non-REM sleep [8,9]. The observed asso-
ciation of narcolepsy with streptococcal [10] and H1N1 [11]
infections and with H1N1 vaccination [12–15] further supports the
concept that narcolepsy is an immune-mediated disease.
The loss of hypocretin-producing neurons characterizes a large
proportion of patients with narcolepsy [16], as do speciﬁc geno-
types such as human leukocyte antigen DQB1*0602 and to a lesser
extent T-cell receptor polymorphisms implicated in autoimmune
pathways [17]. Two types of narcolepsy are currently recognized
in the revised International Classiﬁcation of Sleep Disorders (ICSD-
3) diagnostic criteria [5]. Type 1 narcolepsy, based upon the actual
or presumed loss or reduction of hypocretin, has either cataplexy
or a reduction in measured cerebrospinal ﬂuid hypocretin-1 level.
By contrast, type 2 narcolepsy is determined by the absence of both
cataplexy and, if a lumbar puncture was performed, reduced cere-
bral spinal ﬂuid hypocretin levels, and is dependent upon
polysomnographic evidence.
The clinical features comprise a symptom pentad of EDS, cata-
plexy, hypnagogic/hypnopompic hallucinations, sleep paralysis, and
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disturbed nighttime sleep (DNS). Although patients have various
combinations of all ﬁve symptoms, themost common symptom, and
often the ﬁrst to appear, is EDS, which is present in all patients. Cata-
plexy, which occurs in approximately 70% of narcolepsy patients
and may not appear until weeks or months after the onset of EDS,
is pathognomonic for narcolepsy [18]. Narcolepsy patients also fre-
quently complain of DNS, with frequent abnormal ﬁndings on
polysomnography, which may be characterized in up to 90% of pa-
tients by awakenings/arousals after sleep onset, increased Stage 1
sleep, and frequent sleep stage shifts [19]. The symptoms of sleep
paralysis and hypnagogic/hypnopompic hallucinations are not as
prevalent as the other symptoms, but aid in making the diagnosis
and can have a substantial impact on the patient when they do occur.
Other sleep symptoms, although not included in the pentad, include
frequent vivid, bizarre, and delusional dreams as well as night-
mares [20–22]. Symptoms of REM behavior disorder (RBD) may also
be present in up to 36% of narcolepsy patients, but these may not
be a primary complaint and RBD may more likely be recognized
during polysomnography [23,24].
Although narcolepsy can have an onset at any age, it appears
usually within the ﬁrst two decades of life, with a median age of
onset of 16 years [25,26]. It often remains undiagnosed until many
years after initial symptomonset [27], a delay that likely results from
aconﬂuenceof factors suchas the lackof symptomrecognitionamong
clinicians [28], the lack of a readily available narcolepsy-speciﬁc
screening instrument, and the presence of physical and neuropsy-
chiatric comorbidities [29–32], some of whichmay have symptoms
that overlap with narcolepsy and result in misdiagnosis [33].
Narcolepsy in childrenmay present differently from that in adults,
with increased 24-h sleep close to disease onset, hyperactivity, and
cataplexy that may not be emotionally induced and may resemble
puppet-like movements [34].
Narcolepsy is associated with a substantial economic burden re-
sulting from higher health care cost and greater resource utilization
than among non-narcoleptic individuals [35]. It reduces function-
al ability, work productivity, quality of life, and psychosocial
functioning [36–38], and also increases the risk of work- and driving-
related accidents [39,40]. A study by Ohayon et al. [41] has also
shown that narcolepsy is associated with an approximately 1.5-
fold higher rate of mortality relative to those without narcolepsy.
As there is no cure for narcolepsy,most patients require lifelongphar-
macologicmanagement, and practice parameters for the treatment of
narcolepsy have been developed, although some years ago (in 2007)
[42,43]. Behavior modiﬁcations such as maintaining a regular sleep
schedule, scheduling unique and long naps timed early in the after-
noon, or short naps (15–20min) distributed across the day may have
favorable effects on daytime performance for patients with narcolep-
sy. There is no established behavioral treatment for cataplexy, although
patients can predict situations likely to trigger cataplexy attacks and
act accordingly. Thus, behavioral treatment may have some comple-
mentary beneﬁts to pharmacologic treatment.
The available pharmacologic therapies include medications that
have been approved for the treatment of speciﬁc symptoms of nar-
colepsy, as well as several that are not approved but are used off-
label because of their recognized utility in managing symptoms
(Table 1). Of the US Food and Drug Administration (FDA)-approved
drugs for narcolepsy, methylphenidate, amphetamines, and
modaﬁnil/armodaﬁnil are approved only for EDS. Sodium oxybate
is approved for both EDS and cataplexy in adults [44] although pub-
lished recommendations also suggest its use for disrupted sleep and
as an option for hypnagogic hallucinations and sleep paralysis [43].
Off-label drugs include antidepressants such as selective sero-
tonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake
inhibitors (SNRIs), and tricyclic antidepressants (TCAs), all of which
are recommended for cataplexy and to a lesser extent for hypna-
gogic hallucinations and sleep paralysis, albeit with a lower level
of recommendation than approved drugs, and hypnotics as an option
for DNS [43]. Therapies approved in the European Union include
sodium oxybate for the treatment of narcolepsy with cataplexy in
adults, modaﬁnil to promote wakefulness in adults with narcolep-
sy, and immediate-release methylphenidate for the treatment of
narcolepsy in adults when modaﬁnil is ineffective and in children
>6 years of age. Published guidelines alsomention selegiline, amono-
amine oxidase inhibitor, as an option for EDS, as well as other drugs
Table 1







Antidepressants including SSRIs, SNRIs, and TCAs No No Cataplexy; option for hypnagogic
hallucinations and sleep paralysis
Amphetamine salts (Adderall, but not Adderall XR) Yes (narcolepsy general indication) No Daytime sleepiness
Methamphetamine (Desoxyn) No No Daytime sleepiness
Dextroamphetamine sulfate (Dexedrine) Yes (narcolepsy general indication) No Daytime sleepiness
Lisdexamfetamine (Vyvanse) No No Daytime sleepiness
Methylphenidate HCl (Ritalin, but not
Concerta/Methylin, Equasym XL)





is ineffective and in
children over 6 years)
Daytime sleepiness
Dexmethylphenidate (Focalin) No No Daytime sleepiness




Armodaﬁnil (Nuvigil) Yes (excessive sleepiness) No Developed subsequent to the guidelines.
Selegiline (Eldepryl, Zelapar) No No Cataplexy and daytime sleepiness.
Sodium oxybate (Xyrem) Yes (excessive sleepiness and cataplexy) Yes (narcolepsy with
cataplexy)
Cataplexy, daytime sleepiness, and
disrupted sleep; option for hypnagogic
hallucinations and sleep paralysis
Mazindol No No Daytime sleepiness and cataplexy
Pitolisant No Submitted to EMA
(narcolepsy)
Daytime sleepiness
Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration; SNRIs, serotonin–norepinephrine reuptake inhibitors; SSRIs, selective serotonin
reuptake inhibitors; TCAs, tricyclic antidepressants.
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not currently available in the United States including mazindol,
ritanserin, and reboxetine. Mazindol is an imidazolidine deriva-
tive that blocks dopamine and norepinephrine reuptake that may
be effective for EDS and cataplexy [45], and is only available in France.
Ritanserin is a serotonin-2 antagonist with potential eﬃcacy for EDS,
and reboxetine is a norepinephrine reuptake inhibitor that may be
effective for cataplexy [43].
A recent practical review of the pharmacologic agents used in
clinical practice provided important information relating to their
putative mechanisms, indications, and side effects; however, in the
clinical setting, decisions on what drug(s) to initiate and when to
modify or change therapy are dependent on a variety of factors that
need to be considered [46,47]. Therefore, the purpose of this article
is to discuss these factors and to provide clinically relevant recom-
mendations for making treatment decisions that can enhance the
effective management of patients with narcolepsy. There are several
new approaches to therapy such as the histamine receptor inverse
agonist/antagonist pitolisant [48] and the non-amphetamine stim-
ulant mazindol [45], which are not available in the United States,
as well as experimental therapies including JZP-110 [49,50] and
hypocretin-based therapies such as hypocretin cell transplanta-
tion [51] or intranasal administration of hypocretin [52]. However,
this article focuses on recommended and readily available thera-
pies. The discussion and recommendations that follow reﬂect, in part,
the authors’ personal clinical experience in narcolepsy manage-
ment, and the American and European experiences only.
2. Treatment selection
In clinical practice, consideration of which drug may be most ap-
propriate for initiating therapy in narcolepsy should be based on
factors relating to the different symptoms, to patient characteris-
tics, and to the attributes of various drugs.
2.1. Symptom-related considerations
Narcolepsy symptomatology is the primary disease-related con-
sideration in determining an approach to patient management. In
particular, treatment decisions are likely to be driven by whether
the patient presents primarily with EDS alone or EDS with other
REM-sleep phenomena and additional symptoms, as a therapy that
is effective for multiple symptoms is usually more appealing in the
latter situation than using different drugs for individual symptoms.
Although sodium oxybate is only approved in adults for EDS and
cataplexy, evidence indicates its utility for DNS and as an option
for other REM-sleep phenomena such as frequent disturbing dreams
and nightmares, hypnagogic hallucinations, and sleep paralysis
[42,43]. Polypharmacy not only increases the complexity of any
disease management but is also likely to decrease adherence and
to increase the risk of drug–drug interactions. Interactions are also
possible with drugs that are being used to treat comorbid condi-
tions, includingpotential interactionsof sodiumoxybatewith sedative
hypnotics and other central nervous system depressants [44].
Cataplexy and EDS are the most recognized symptoms of nar-
colepsy and initial treatment typically targets these symptoms. EDS,
which usually precedes cataplexy as a presenting symptom, is often
treated with modaﬁnil as initial therapy, especially if EDS is present
in the absence of cataplexy. However, modaﬁnil and most of the
stimulant drugs used to treat EDS have little effect on cataplexy or
other REM sleep-associated symptoms, and, conversely, most
anticataplectic antidepressants have little beneﬁcial effect on EDS
[43]. While no drugs are FDA approved for the other symptoms of
the pentad, the presence of these other symptoms in patients should
result in consideration of medications that can either be used to
supplement those for EDS and cataplexy or address the widest pos-
sible group of symptoms.
Treatment decisions should also reﬂect the principal com-
plaint of the patient, which may not necessarily be the same as the
presenting symptoms. Importantly, some symptoms may not be
spontaneously reported by patients for a variety of reasons includ-
ing that the patients do not realize that the symptoms are part of
narcolepsy (eg, cataplexy), or they may be too embarrassed to raise
certain issues on their own (eg, frequent unpleasant and bizarre
dreams). A recent study reported that, in addition to symptoms of
the narcolepsy pentad, 42.9% of patients complained of trouble func-
tioning or concentrating during the day, and that one-quarter of
patients (25.8%) reported diﬃculties with activities of daily living
[32]. Table 2, adapted from Overeem et al. [53], is a comprehen-
sive list of topics that can be recommended for initiating discussion
in a clinical interview. These topics provide a starting point for con-
sidering approaches to therapy by eliciting information from patients
on the narcolepsy symptoms that are less well known (ie, DNS, sleep
paralysis, unpleasant dreams, depressive symptoms, and overweight/
obesity) but nevertheless result in a substantial impact on the life
of the patient, as well as on associated affects such as memory/
cognitive impairment and daily function.
To summarize initial treatment selection, we propose to initi-
ate narcolepsy therapy in at least two successive steps. For most
patients, the ﬁrst step requires an agent that is effective for treat-
ing daytime sleepiness. Treatment of EDS should be considered
mandatory, as EDS is present in all patients and has practical im-
plications with respect to the risk of driving- or work-related
accidents. If EDS is present in the absence of cataplexy, treatment
can be initiated with monotherapy using either modaﬁnil or sodium
oxybate, with the latter being a better choice if any ancillary fea-
tures of narcolepsy are present (sleep paralysis, hypnagogic/
hypnopompic hallucinations, DNS, nightmares, etc.). The second step
may require the use of other agents depending on persistence and
discomfort related to associated symptoms and their impact on
patient function. Multiple medications are also likely to be re-
quired in cases of uncontrollable EDS or cataplexy, with the use of
sodium oxybate and/or modaﬁnil plus an “as-needed” stimulant
(methylphenidate or amphetamine). Behavioral measures such as
naps, avoiding sedentary activities, and avoiding driving or dan-
gerous work situations should also be considered in these cases.
2.2. Patient-related considerations
While symptomatology may suggest an initial approach to nar-
colepsy management, age is an important factor for making
treatment decisions.
As onset is typically in children and adolescents, an early diag-
nosis followed by early initiation of therapy is critical to minimize
emotional and developmental problems including reduced scho-
lastic achievement. Pediatric recommendations for the treatment
of narcolepsy have not been established, and while few drugs have
been evaluated for eﬃcacy or toxicity in children, treatment of pe-
diatric narcolepsy is generally considered similar to that of adults
[46]. Other than amphetamines and methylphenidate stimulants,
no other medications have been approved by the FDA for the treat-
ment of narcolepsy in children. In Europe, armodaﬁnil and
amphetamines have not been approved for narcolepsy by the Eu-
ropean Medicines Agency (EMA), and only immediate-release
methylphenidate is approved for the pediatric population. However,
methylphenidate and the amphetamines can be associatedwith sup-
pression of growth [54], may predispose to drug abuse and addiction,
and severe rashes, although rare in clinical practice, andmay bemore
likely to occur in children on modaﬁnil/armodaﬁnil [55,56]. Limited
clinical reports of children with narcolepsy suggest the eﬃcacy and
tolerability of modaﬁnil for EDS, venlafaxine for cataplexy, and
sodium oxybate for most symptoms, although multiple medica-
tions are used in some patients [57–59]. Of note, armodaﬁnil is
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similar to modaﬁnil in eﬃcacy for EDS, but in contrast to modaﬁnil,
which requires twice-daily dosage, armodaﬁnil is taken once per
day. Thus, armodaﬁnil may be of interest as a ﬁrst choice especial-
ly in children whomaymiss the second intake of modaﬁnil at lunch,
or in case of sleep-onset insomnia due to the secondmodaﬁnil dose.
However, parents might be concerned about long-term pharma-
cologic treatment in a child. Therefore, when possible, a behavioral
approach can be taken to control sleepiness using regularly sched-
uled naps, but if cataplexy impacts quality of life or safety issues,
sodium oxybate should be initiated.
As increasing age and overweight/obesity convey an increased
risk of cardiovascular disorders including hypertension and heart
failure, a high percentage of non-blood pressure dippers has been
reported in patients with narcolepsy that may be of clinical rele-
vance by predisposing to cardiovascular events [60]. This latter
ﬁnding implied the involvement of hypocretin in multiple physi-
ologic functions such as energy homeostasis and cardiovascular
control and suggested changes in the autonomic nervous system
in hypocretin-deﬁcient narcolepsy [61]. For these reasons, in older
and/or obese narcoleptics, it may be appropriate to limit the use
of sodium oxybate because of its high salt content. However, an-
ecdotally, sodium oxybate has been used with salt restriction and
diuretics, although the eﬃcacy and safety of this combination need
to be conﬁrmed. The choice of methylphenidate or amphetamines
is also less than optimal in an older population, as these drugs are
contraindicated in patients with cardiovascular disorders and glau-
coma. Some antidepressants, especially TCAs, are contraindicated
in an older population due to the risks associated with their se-
dating effect, confusional-state urinary retention, and potential for
cardiac arrhythmias and induction of orthostatic hypotension [62].
For women of childbearing potential who are using oral con-
traceptives for birth control, the use of modaﬁnil/armodaﬁnil needs
to be discussedwith regard to potential interactions that may impact
the effectiveness of contraception [55,56]. In these individuals, an
increased dose of ethinylestradiol up to 50 μg per day, an all-
progesterone oral contraceptive, or an alternative method for birth
control should be employed. Another contraindication for the use
of sodium oxybate is the need for alertness at night among indi-
viduals with infants or young children, especially in the case of a
single parent.
As narcolepsy management is a long-term endeavor, the patient
should be regarded as an active participant in treatment deci-
sions. Discussions should include information on all the available
treatment options, focusing on what can realistically be expected
with regard to eﬃcacy and adverse effects. The purpose of these dis-
cussions is to elicit informed feedback from the patient as to what
might best ﬁt with their symptoms, goals, and lifestyle, thereby in-
creasing the likelihood of higher treatment adherence. Patients
should only make changes to their medication regimen under the
advice of the clinician.
2.3. Therapy-related considerations
The clinician should have complete familiarity with the mecha-
nisms of action, dosing regimens, and the rationale for speciﬁc use
of each of the medications [46]. Therapies should be initiated at an
appropriate level, and should be titrated up or down as necessary
when the need arises. Balance needs to be maintained between ef-
ﬁcacy and side effects, as complete elimination of EDS in narcolepsy
is rare. Treatment with a dosage that is too low, in an attempt to
avoid side effects, can result in discontinuation due to lack of eﬃ-
cacy and adverse effects with only partial improvement of EDS.
Titration rate to maximal eﬃcacy while minimizing side effects
should be done on an individual basis. However, even FDA-approved
maximal doses, such as for modaﬁnil, may not be fully effective in
relieving daytime sleepiness; higher doses (up to 600 mg per day)
[63], although recommended, may not be reimbursed by health-
care insurers. Discussions about side effects should be individualized
Table 2
Suggested topics to cover in the clinical interview for eliciting information from patients on narcolepsy symptoms and their effects, and which may provide a basis for making
treatment decisions.
Topic Issues for discussion with patient
General Age at onset of EDS and cataplexy, and initial presenting symptoms; are there any possible triggers around onset (eg,
infection, vaccination, trauma, or concurrent neurologic illness)?
Sleepiness How does sleepiness interfere with daily function, with regard to the magnitude of the effects and the quality of the
outcomes? What is the pattern of excessive sleepiness: continuous somnolence or sleep attacks? What is the frequency and
duration of both involuntary and planned sleep episodes? Are sleep episodes freshening? Can sleep be resisted? Are there
dreams or similar phenomena during short naps? What circumstances worsen or improve sleepiness? Since onset, has there
been any freedom from sleepiness? Variability of daytime sleepiness during the week versus weekends.
Cataplexy What is the description of a typical attack, including pattern of weakness? Are attacks mostly partial or complete, unilateral
versus bilateral? What is the frequency and duration of episodes? Ensure there is no loss of consciousness. Inquire about
spectrum of triggers. Have there been any physical injuries?
Nocturnal sleep Habitual sleep duration and sleep–wake schedule during the week versus the weekend; subjective sleep latency, and number
and duration of awakenings; symptoms of other possible sleep disorders (such as SDB or RLS). Assess sleep hygiene.
Hallucinations Hypnagogic or hypnopompic? Duration, frequency, and content; associated symptoms of fear and anxiety. Place and time of
occurrence of hallucinations.
Sleep paralysis Duration and frequency. Co-occurrence with hypnagogic/hypnopompic hallucinations?
Automatic behaviors Establish any examples of automatic behaviors and their circumstances and frequency.
Dreams Frequent, vivid, bizarre dreams, out-of-body experiences, dreams and naps.
Weight change Current weight and height to calculate BMI. Was there any change around the onset of narcolepsy symptoms? Current
stability of weight; is there any inﬂuence of medication on weight?
Eating habits Abnormal appetite (eg, binge eating or eating at night); inﬂuence of meals and their type (eg, high carbohydrate load) on
(postprandial) sleepiness.
Mood/anxiety Are there mood disturbances? Is there a history of depression, anxiety, panic attacks, phobias, or suicide ideation?
Other symptoms Are there any memory or concentration complaints? If appropriate, ask about sexual problems. Speciﬁcally assess fatigue
(separate from actual sleepiness).
Psychosocial aspects Have narcolepsy symptoms of sleepiness or cataplexy inﬂuenced social interactions at school or work? Ask about driving.
Family history Are there any relatives with narcolepsy, daytime sleepiness, or other sleep disorders?
Comorbidities and co-medications History of cardiovascular diseases, sleep apnea syndrome, diabetes, restless legs syndrome, RBD, and sleepwalking/enuresis.
Review of medications or substances acting on central nervous system.
Table adapted with permission from Overeem et al. [53].
Abbreviations: BMI, body mass index; EDS, excessive daytime sleepiness; RBD, rapid eye movement sleep behavior disorder; RLS, restless legs syndrome; SDB, sleep-
disordered breathing.
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depending upon the patient’s age, prior drug experience, person-
ality, and educational level among other considerations. Side effects
can occur after therapy initiation and then dissipate with therapy,
such as is common with modaﬁnil and sodium oxybate, so prema-
ture termination may be inappropriate. Drugs that require tapering
rather than abrupt cessation include antidepressant anticataplectic
agents, which can induce status cataplecticus [64]. A switch from
amphetamines to modaﬁnil or methylphenidate, or the converse
switch, can be performed abruptly, whereas a change from
anticataplectic agents to sodium oxybate should be done with
gradual antidepressant reduction and increasing sodium oxybate
titration [65].
Most narcolepsy drugs are FDA – controlled substances, Sched-
ules II, III or IV, which may be disconcerting to both patients and
physicians, for the former because of concernwith addiction or abuse
potential, and for the latter because of the greater burden of record
keeping. Dextroamphetamine, lisamphetamine, methamphet-
amine, and methylphenidate are Schedule II controlled substances
(high potential for abuse, which may lead to severe psychologic or
physical dependence), sodium oxybate is a Schedule III controlled
substance (less potential for abuse, but may lead to moderate or low
physical dependence or high psychologic dependence), and
modaﬁnil/armodaﬁnil are Schedule IV controlled substances (a low
potential for abuse relative to the drugs or other substances in Sched-
ule III). Although excessive dosage and associated adverse effects
of stimulant medications have been reported in narcolepsy [66], in
clinical practice, patients with narcolepsy rarely abuse drugs for nar-
colepsy or develop addictions [67,68]. The effect on the reward
system that predisposes to reduced addictionmay be associatedwith
hypocretin loss [69].
Drug cost, whether borne by the patient or by managed care, can
present a barrier to treatment. More recently approved medica-
tions are typically associated with high costs, and although some
of the drugs for narcolepsy are available as generics (antidepres-
sants, methylphenidate, amphetamines, and modaﬁnil), they may
not always be the appropriate choice despite providing a cost ad-
vantage. Costs should be considered, but the patients ultimate choice
of treatment should be based on clinical considerations as to which
medication provides the greatest beneﬁt and the best side-effect
proﬁle. Higher costs may be offset by the greater functionality, pro-
ductivity, and quality of life that can be achieved.
3. Medication strategies
3.1. Methylphenidate and amphetamines
Methylphenidate and amphetamines were available before the
new agents such asmodaﬁnil/armodaﬁnil and sodium oxybate. Their
usefulness is primarily for EDS, except for some mild cases where
they have not shown to be effective for cataplexy and other symp-
toms of narcolepsy. Although cheaper than the newer alternatives,
their usefulness is limited by their abuse potential and side-effect
proﬁle [66]. Methylphenidate has now been relegated to second-
line therapy, with amphetamines andmazindol as third-line therapy,
the latter at least in France, as there are few clinical trial data avail-
able on their eﬃcacy and safety [43]. If a patient cannot take
modaﬁnil or armodaﬁnil or sodium oxybate, or more frequently
when these compounds are not fully effective for EDS, then meth-
ylphenidate or amphetamine stimulants, as either extended-
release forms taken one or two times per day or short-acting forms
taken up to four times a day, can be useful. Higher-than-
recommended doses (60mg per day for methylphenidate and 60mg
per day for amphetamine) have been associated with more fre-
quent hospitalizations, cardiac arrhythmias, and psychiatric
disturbances in narcolepsy patients [66].
3.2. Antidepressants
Few data exist regarding the eﬃcacy of antidepressants (SSRIs,
SNRIs, and TCAs) on cataplexy [70]. However, in clinical practice,
case reports have suggested that they can be effective [71–73], es-
pecially those with the strongest norepinephrine reuptake inhibition.
Thus, SNRIs are the most widely used antidepressants for cata-
plexy, particularly venlafaxine, which may be effective for cataplexy
within 48 h at low doses. Because of its short duration of action,
the extended-release form is preferable, starting at a low dose
(37.5mg), but higher doses are often needed (75–300mg). However,
they are limited by side effects that can include insomnia, mental
stimulation, and reduced sexual function, and may precipitate other
sleep disorders such as RBD [74] and restless legs syndrome (RLS)
[75]. They are neither FDA nor EMA approved for cataplexy but can
be useful as an alternative to sodium oxybate.
3.3. Modaﬁnil/armodaﬁnil
These medications are effective for EDS but have no effect upon
the ancillary symptoms of narcolepsy. Although rare in clinical prac-
tice, they can be associated with severe rashes in children [55,56]
and can reduce the eﬃcacy of oral contraceptive agents [55,56].
When indicated, they are best taken ﬁrst thing in the morning on
an empty stomach. If headaches occur, temporary adjustment of the
dose is usually all that is required. Most patients require the
maximum approved dosage (400 mg approved and sometimes up
to 600 mg per day for modaﬁnil), but some patients do quite well
even on low doses such as 100 mg of modaﬁnil or 50 mg of
armodaﬁnil. In combination with sodium oxybate, they have been
shown to enhance the improvement of EDS [76]. Among patients
taking modaﬁnil/armodaﬁnil who may be required to perform de-
manding tasks during the course of their daily activities, a
supplementary late afternoon dose of a short-acting stimulant, such
as Dexedrine or regular methylphenidate, can be used.
3.4. Sodium oxybate
Sodium oxybate, which is FDA approved for sleepiness and cata-
plexy in adults, is the only medication that can treat, and is
recommended for, all the symptoms of narcolepsy [42,43]. Often
well tolerated, side effects are very variable from one patient to
another. Side effects are usually mild to moderate at worst, but pa-
tients may develop nausea, confusion, anxiety, depressive symptoms,
RLS, and sleepwalking, or enuresis that may limit its use. In clini-
cal practice, the confusion and neuropsychiatric effects at treatment
initiation have been found to be due, at least in part, to a dose that
does not rapidly induce sleep, as some patients may take up to 2 h
to fall asleep after dosing, thereby causing symptoms of confusion
and incoordination in the patient who is still ambulatory at that time.
A more rapid increase in dose can improve this situation, and ti-
tration to effect is a critical component of patient management with
sodium oxybate. Nausea can be helped by adding ﬂavored water
to the sodium oxybate solution, which has a salty taste, or by ad-
justing of the dosage. An oral antiemetic such as a 5-HT3 antagonist
(eg, ondansetron) has been used clinically in some patients to help
control the nausea. Although this medication best taken on an empty
stomach, as a meal may reduce the eﬃcacy, adding of small amount
of food, such as a cracker, may help mask the taste.
Although gamma-hydroxybutyrate including sodium oxybate-
related deaths have been reported, these events are mainly related
to an overdose or illicit use, or in association with concomitant uti-
lization of other sedative drugs [77].
Initial concerns regarding abuse have not been borne out since
its approval [78], and its low abuse in the clinical setting may be
especially aided in the United States by the requirement of central
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pharmacy dispensing. Although its dosing regimen has been of
concern to physicians, in clinical practice, few patients have been
bothered by taking the medication twice at night. Clinical practice
has shown that some patients do well with a single nightly dose,
while in others the ﬁrst and second doses have been adjusted ac-
cording to clinical needs without loss of eﬃcacy [79].
If cataplexy or EDS is severe, initiating the patient on sodium
oxybate plus venlafaxine (for cataplexy) or sodium oxybate plus
modaﬁnil (for EDS) is a reasonable initial plan until the sodium
oxybate is effective, at which point the other medication may be
tapered off.
4. Evaluation of treatment response
Outcomemeasures represent an important component of moni-
toring and optimizing treatment for any disease. In the case of
narcolepsy, regular assessment after initiation of treatment is a useful
approach to drive changes in therapy such as dose adjustment or
switching of medications, especially because the level of improve-
ment may not be able to be predicted.
Assessment measures should be based on symptoms, patient
complaints, and the goals of the patient with regard to treatment.
An important attribute of anymeasure to be used in evaluating treat-
ment response is its demonstration of sensitivity to change. Objective
measures such as the Multiple Sleep Latency Test, the Mainte-
nance of Wakefulness Test, the Sustained Attention to Response Task
[80], and the Psychomotor Vigilance Test may be useful for quan-
titatively evaluating clinical outcomes. However, these objective
measures of sleepiness or vigilance may not necessarily correlate
with patient function or symptomatic complaints. Additionally they
require time, and are complex and not readily reimbursable by in-
surance carriers. Thus, these tests are infrequently used as a routine
measure of treatment eﬃcacy in narcolepsy, but the Maintenance
of Wakefulness Test should be proposed for assessment of those who
may be employed as drivers.
Of greater relevance from the patient’s perspective are subjec-
tive measures that focus on the patient complaint and their overall
goal of treatment. Several patient-reported outcomes (PROs) address
sleep and sleepiness-related outcomes including the Epworth Sleep-
iness Scale (ESS) [81], often used for narcolepsy screening, and the
Karolinska Sleepiness Scale (KSS) [82]. While both the ESS and the
KSS measure the magnitude of sleepiness over different recall
periods, the Functional Outcomes of Sleep Questionnaire [83] as-
sesses the impact of excessive sleepiness on activities of daily living.
Although infrequently used in clinical practice in narcolepsy pa-
tients, the Insomnia Severity Index (ISI) [84] may also be considered
an option that could be of potential value in some patients at initial
and follow-up evaluations, depending on the patient’s symptom-
atic complaints. The ISI is a short self-report questionnaire that
assesses the nighttime and daytime components of insomnia, and
in the absence of a speciﬁc DNS measure may act as an assess-
ment for the presence and impact of DNS in patients with narcolepsy.
Other generic measures focus on quality of life, such as the 36-
or 12-item Short Form questionnaires [85,86] and the ﬁve-dimension
European Quality of Life questionnaire [87], or on speciﬁc prob-
lems such as depression using the nine-item Patient Health
Questionnaire [88] or the Beck Depression Inventory [89]. Ideally,
a sleep-related measure as well as a more general health-related
quality-of-life measure should be regularly used to monitor pa-
tients for treatment effects and general health. The effectiveness of
drugs used to treat cataplexy, hallucinations, sleep paralysis, and
sleep disturbance is diﬃcult to evaluate, as the methods used to
assess both their frequency and intensity remain variable and
complex (eg, recall by history only, by scale, by diaries, or by video
recordings). However, at least the use of speciﬁc diaries is recom-
mended for monitoring the persistence of such symptoms.
Alternative methods of capturing PROs exist including interac-
tive voice response systems, patient portals, or electronic medical
records. These methods enable more frequent assessment without
the need for clinical oﬃce visits, and they also facilitate record
keeping and data analysis.
In regard to the changes that may be observed on objective and
PRO measures, an important issue in narcolepsy is determining the
clinical signiﬁcance of the changes, as there is a lack of informa-
tion on what constitutes clinically meaningful improvements. It
should also be noted that, while a patient is often the best judge
of treatment response, the patient’s perspective may not necessar-
ily coincide with that of the clinician, nor does a patient’s perceived
satisfaction with the treatment necessarily reﬂect the response that
could potentially be achieved. In this regard, the patient’s family
or teachers, when children are involved, should be considered
as a valuable source for evaluating treatment response as the
observations of family members may be inconsistent with the
patient’s perceptions or the patient’s report at a clinical visit.
5. Managing comorbid conditions
5.1. Comorbid conditions
Several studies have shown the frequent occurrence of one or
more comorbidities among narcolepsy patients, including medical
and neuropsychiatric conditions [29–32]. In addition to contribut-
ing to the diagnostic delay [27], some disorders have symptoms that
overlap with narcolepsy, increasing the complexity of diagnosis, and
their management may rely on treatments that mask narcolepsy
symptoms, such as antidepressants for depression, stimulant use
for attention-deﬁcit hyperactivity disorder, or continuous positive
airway pressure (CPAP) for obstructive sleep apnea (OSA).
Depressive symptoms are frequent in patients with narcolepsy,
especially in the context of cataplexy, but less frequent is a formal
diagnosis of major depressive disorder [90]. However, patients with
mood disorders should be screened for suicidality prior to initiat-
ing sodium oxybate therapy, during therapy, and especially after any
increases in dosage. Although a risk of suicide has been recog-
nized in patients with sleep disorders [91,92], including narcolepsy
[93], sedative neuropsychiatric medications in combination with
sodium oxybate may increase the suicide risk [78]. While vali-
dated questionnaires such as the Columbia Suicide Severity Rating
Scale [94] are available to monitor this risk, the patient’s partner
or family should also be informed about watching for behavioral
changes that may be indicative of suicidality. In addition, neuro-
psychiatric medications may impair awareness of ingested
medication, thereby leading to an accidental overdose.
Comorbid metabolic conditions such as diabetes may be of par-
ticular relevance to narcolepsy because of the associated obesity and
weight control issues. While narcolepsy itself is not directly asso-
ciatedwith insulin resistance or glucose tolerance [95,96], narcolepsy
treatments may have metabolic effects. Sodium oxybate can in-
crease lipolysis, which may contribute to weight loss [97], and
stimulants may affect glucose control.
Patients with narcolepsy with a history of cardiovascular dis-
eases should not be treated with stimulants except with low doses
of modaﬁnil, low doses of long-release methylphenidate in the
absence of modaﬁnil eﬃcacy, or with pitolisant, where available.
However, careful follow-up is required in these patients.
Patients with narcolepsy also display a variable array of complex
motor phenomena during sleep, encompassing both REM- and non-
REM-related parasomnias. REM sleep without atonia together
with elementary and complexmotor behavior up to clear-cut oneiric
enactment, considered an equivalent of RBD, frequently occur
in narcolepsy. Non-REM-related parasomnias, somnambulism,
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sleep-related eating syndrome, and enuresis are also reported in pa-
tients with narcolepsy.
5.2. Treatment-related exacerbation of comorbidities
Narcolepsy treatment may result in exacerbation or precipita-
tion of sleep disorders, including OSA, periodic limb movements
(PLMs), RLS, and RBD [98].
In particular, PLMs and RLS, which have been reported to be
present in up to 50% and 25%, respectively, of patients with narco-
lepsy [24,99,100], are associated with a higher nighttime arousal
index, thus further disrupting sleep and contributing to daytime
sleepiness and fatigue [101–103]. PLMs and RLS can be exacer-
bated by drugs that increase central nervous system sedation such
as sodium oxybate [98,104], as well as antidepressants [74,75], and
therefore may require a switch in therapy. RBDmay also be induced
by antidepressants in patients with narcolepsy [105].
OSA is a comorbidity that is related to increased weight and
obesity, has a high prevalence in narcolepsy [106–108], and can
lead to a lack of narcolepsy recognition [27,109]. Central sleep apnea
and OSA syndromes should be excluded before prescribing
sodium oxybate, and sleep apnea treated prior to initiating sodium
oxybate therapy. The treatment, usually by CPAP, needs to be
maximized before initiating treatment with sodium oxybate, which
can also precipitate or exacerbate OSA [110]. However, sodium
oxybate is also associated with weight loss in patients with
narcolepsy [111].
5.3. Pregnancy
An international survey of 34 sleep medicine clinicians with ex-
perience in narcolepsy highlighted that substantial variability exists
among clinicians and across countries regarding the management
of narcolepsy in pregnancy [112]. The available but limited evi-
dence suggests that, despite narcolepsy drugs receiving a Schedule
C classiﬁcation for pregnancy (ie, risk cannot be ruled out), the risks
of toxicity resulting from the utilization of narcolepsy drugs during
pregnancy may be overestimated, with little or no evidence for tera-
togenicity at therapeutic doses [112]. When the pregnancy is
planned, management options can be discussed in advance; when
unplanned, consideration should be given to adjusting medica-
tion regimen depending on the stage of pregnancy. Women going
through pregnancy even without medications have a 2% risk of fetal
malformation in narcolepsy [113], similar to the general popula-
tion. While it is necessary to psychologically prepare women for the
risk of fetal malformation even under normal clinical conditions,
the decision to continue or withhold narcolepsy medications during
pregnancy should be made by an informed patient after weighing
the risks and beneﬁts. Although, ideally, patients should discon-
tinue medication during the whole time of conception and
pregnancy, this may not be possible, especially if the pregnancy is
unplanned. Potential management options should include staying
on medication with dose reductions, changing medication if ap-
propriate, or stopping themedication. However, treatment cessation
may not be advisable in some patients if narcolepsy symptoms are
severe and there is a risk of injury to the mother or fetus or an in-
ability to manage daily activities. Clinicians should also note that
the best time to avoid medications is within the ﬁrst 60 days of
pregnancy.
There is little information available on the use of narcolepsymedi-
cations in nursing mothers. Most hypnotics are contraindicated in
nursing mothers due to concerns regarding the depressant effect
in the infant, so similarly it would be unwise to use sodium oxybate,
especially as it is not known whether it is excreted in human milk
[44]. However, sodium oxybate has a short half-life, and in clinical
practice somemothers have expressedmilk before their nightly dose
to give to the infant. Modaﬁnil, methylphenidate, amphetamines,
and antidepressants have no speciﬁc contraindications in nursing
mothers.
6. Managing concomitant medications and other substances
Patients with narcolepsy have a higher prevalence of comorbid
conditions relative to matched controls, and they also have signiﬁ-
cantly higher utilization of a variety of prescriptionmedications [29].
Therefore, an understanding of medication mechanisms of action
is critical when making narcolepsy treatment decisions. Examples
include the risk of serotonin syndrome due to combinations of an-
tidepressants, and sodium oxybate, which is a central nervous system
depressant and may be associated with respiratory depression.
Therefore, if treatment with sodium oxybate is considered, not only
are sedative hypnotics and alcohol contraindicated [44] but also the
use of other central nervous system depressants, such as opioids
and divalproex sodium, should be discontinued or reduced [44], with
patients being closely monitored if the use of other central nervous
system depressants is required. A summary of key drug interac-
tions is provided in Table 3.
The use of lifestyle substances such as caffeine, nicotine, alcohol,
cannabis, and other drugs should be assessed and discussed with
the patient, and appropriate therapeutic recommendations made.
Prior to diagnosis, many patients use caffeine excessively to improve
alertness the general stimulation effects are not pleasant even when
and patients readily give up or reduce caffeine use when on a spe-
ciﬁc medication for alertness. Case reports suggest that nicotine may
mask or relieve symptoms of narcolepsy, including EDS and even
cataplexy [114,115]. Such an interaction is supported by limited data
suggesting that nicotine addiction may be mediated by hypocretin
pathways [116]. Although narcolepsy symptom relief may be viewed
as a beneﬁt of nicotine and may thus be a barrier to smoking ces-
sation in narcoleptics, the act of smoking is itself of concern because
of the risk of falling asleep while smoking resulting in injury and
damage [114].
Several of the drugs used to treat narcolepsy have warnings re-
garding the concomitant use of alcohol, including sodium oxybate
[44]. However, many patients will be reluctant to completely forego
alcohol, and therefore a realistic approach should be taken when
providing information on these interactions. Young adults should
be especially advised regarding interactions with alcohol and em-
phasis should be placed on methods to minimize such interactions,
including minimal consumption, type of alcohol (beer, wine, or
spirits), and timing of alcohol intake. Alcohol should not be present
in the body concurrently with sodium oxybate. Timing is likely to
be most relevant for sodium oxybate, which is taken only at night,
and consideration should be taken of the drug’s dosing regimen and
the pharmacokinetics of alcohol; skipping the ﬁrst sodium oxybate
dose at night may often be good advice in situations of alcohol
consumption.
Nothing has been published about the effects of cannabis on nar-
colepsy or its interaction with drugs during narcolepsy therapy. Such
interactions may become an increasingly open issue with the wider
availability of medical marijuana and the recent loosening of re-
strictions for recreational use in several US states. Anecdotal evidence
from clinical practice suggests that there do not seem to be any
interactions, although concomitant use of cannabis-containing
products is not recommended and may increase some vigilance
problems.
7. Summary
Narcolepsy remains a challenging disease for both diagnosis and
treatment. However, once the disorder is diagnosed, the challenge
of treatment can be lessened if an appropriate and careful
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approach is used when considering treatment options. While
symptom presentation, whether EDS alone or with cataplexy and
other
symptoms, is an important driver of treatment decisions, patient
management needs to incorporate the clinical perspective yet take
a patient-centric approach; the patient should be an active partic-
ipant in the decision-making process. Clinical considerations include
the presence of comorbid conditions and their treatment, and their
relationship to the different pharmacologic options that are avail-
able for narcolepsy. The associated dose regimens need to be clearly
conveyed to the patient, taking into account the patients goals and
lifestyles, as well as broad recommendations that can then be nar-
rowed and optimized by individualizing the treatment and its dosing
for each patient.
Narcolepsymanagement also requires regular evaluation to iden-
tify when changes in medication may be required. Although there
is a need for systematic and standardized outcome assessment in-
struments speciﬁc for narcolepsy, a wide variety of measures are
available, with the choice of measures based on the outcomes that
need to be evaluated. Regardless of the measures used, patients
should be evaluated regularly for determining the presence and se-
verity of symptoms, their effects on daily function, whether treatment
goals are beingmet, and the eﬃcacy and safety of medications, which
will facilitate effective long-termmanagement and improve the lives
of narcolepsy patients and their families.
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